# A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

> **NCT01774851** · PHASE2 · TERMINATED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 84 (actual)

## Conditions studied

- HER-2 Gene Amplification
- Esophagus Cancer
- Gastroesophageal Junction Cancer
- Stomach Cancer

## Interventions

- **DRUG:** MM-111
- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01774851
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-07
- **Final completion:** 2015-12
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** DSMB recommendation due to lack of efficacy. There were no safety signals.
- **Last updated:** 2017-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01774851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01774851, "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01774851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*